缅北禁地

Skip to main content

Staff Profile

Professor Nicola Curtin

Professor of Experimental Therapeutics

  • Email: nicola.curtin@ncl.ac.uk
  • Telephone: +44 (0) 191 208 4415
  • Fax: +44 (0) 191 208 4301
  • Address: 缅北禁地
    Translational and Clinical Research Institute
    缅北禁地 Centre for Cancer
    Faculty of Medical Sciences
    Paul O'Gorman Building
    缅北禁地 upon Tyne
    NE2 4HH
Background

Introduction

Professor of Experimental Cancer Therapeutics, since 2006, having worked in 缅北禁地 since 1982. More than 30 years’ experience in the development and biological evaluation of novel drugs to treat cancer and the development of biomarkers to predict and assess their effects. Major interest is in targeting the DNA damage response see    

ROLES AND RESPONSIBILITIES

Team Leader: DNA damage response

Member of FMS Equality, Diversity and Inclusion Team

Former member of both Senate and Council (2015-2020)

Chair NCRI CTRad Workstream 1

QUALIFICATIONS

BA (Biology) University of York 1975

MSc Liver carcinogenesis Manchester University 1977

PhD Biochemistry of liver carcinogenesis University of Surrey 1981

PREVIOUS POSITIONS

2002-6           Senior Lecturer in Cell Biology and Experimental Therapeutics of Cancer, Northern Institute for Cancer Research, University of 缅北禁地 upon Tyne.

1996-2002 Lecturer in Cell Biology and Experimental Therapeutics of Cancer, Cancer Research Unit, University of 缅北禁地 upon Tyne.

1990-6         Senior Research Associate, Cancer Research Unit, University of 缅北禁地 upon Tyne.

1985-1990    Research Associate, Cancer Research Unit. University of 缅北禁地 upon Tyne.

1982-1985    Research Associate, Public Health Laboratories, 缅北禁地 upon Tyne.

MEMBERSHIPS

British Association Cancer Research

American Association Cancer Research

NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad)

Yorkshire Cancer Research Scientific Advisory Board

Science Foundation Ireland Scientific Advisory Board

Research Council of Norway Strategic Initiative on Cancer Research: Panel member

Council of Life Sciences of OTKA (Hungarian Scientific Research Fund)

Leukaemia and Lymphoma Research (site visit panel)

CRUK-EORTC committee on NCI compounds

 

Research

 

RESEARCH INTERESTS

My work focusses primarily on how DNA damage is signalled to cell cycle checkpoints and DNA repair, otherwise known as the DNA damage response (DDR), and how this can be used for improved cancer therapy. The most exciting discovery from my lab was the synthetic lethality of PARP inhibitors (PARPi) in cancers lacking homologous recombination DNA repair (HRR), e.g. due to BRCA mutations. This discovery, published in 2005 in Nature has led to a major paradigm shift in the treatment of cancers and now 4 PARPi (including rucaparib, that I helped to develop from 1997 to 2010) are approved for cancer therapy.

Current Work

1.       The evaluation of drugs targeting DDR pathways: PARP, DNA-PK, ATM, ATR CHK1, Wee1

  • PARP signals and promotes the repair of DNA breaks (mostly single-stranded) that are the most common form of naturally occurring DNA damage. DNA-PK signals and promotes the repair of DNA double strand breaks that are highly cytotoxic and ATM/CHK2 and ATR/CHK1/Wee1 signal DNA damage to cell cycle checkpoints so cells don’t try to replicate with damaged DNA.
  • PARP inhibitors

2.       The identification and therapeutic exploitation of the dysregulation of the DNA damage response, which is a common characteristic of cancer. In particular, identifying determinants of sensitivity to drugs that target components of the DNA damage response, like PARP and ATR inhibitors that may subsequently be used to develop predictive biomarkers to stratify patients to appropriate therapy.

  • The development of an assay for homologous recombination DNA repair (HRR) function that can be used on patients’ tumour cells. HRR defects are largely tumour-specific and a determinant of sensitivity to PARP inhibitors so this allow patient stratification for PARP inhibitor therapy
  • Identification that common cancer-associated defects in the DNA damage response make cells more sensitive to killing with ATR inhibitors.

3.       The development of pharmacodynamic biomarkers to monitor the activity of novel drugs targeting the DNA damage response (published assays are for PARP and ATR inhibitors) that can be used in clinical trials.

Other Expertise

Antifolates, cancer metabolism, nucleoside transport


Postgraduate supervision

PhD students: 22 completed on time, 2 awarded the faculty prize, 3 ongoing

MD students: 4 completed on time, 1 ongoing

MSc Oncology (web-based learning) : Module leader of Cancer Pharmacology module

 

Esteem Indicators

REF impact case 2014

Prize: CR UK Translational Research Prize Nov 2010

Committee membership

Yorkshire Cancer Research Scientific Advisory Board

NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad)

Council of Life Sciences of OTKA (Hungarian Scientific Research Fund, annually)

Science Foundation Ireland Scientific Advisory Board (occasional)

Leukaemia and Lymphoma Research (site visit panel)

Research Council of Norway Strategic Initiative on Cancer Research: Panel member (approx. biannually)

Editorial Board

Expert Reviews in Molecular Medicine - Editor in Chief

British Journal of Pharmacology

Cancers

American Journal of Translational Research

Other

Regular reviewer of grants proposals submitted to CRUK, MRC, Wellcome

Regular reviewer of manuscripts submitted to, Nature, Nature Medicine, Nature Reviews Cancer, Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, Oncogene, Oncotarget

Invited Reviews: Nature Reviews Cancer, Nature Reviews Drug Discovery, Lancet Oncology

 Funding (current)

Intermittent PARP inhibitor in recurrent ovarian cancer (IPIROC). A Mukhopadhyay and NJ Curtin (Co PI) £30,000 seedcorn funding CRUK DBT/ Wellcome Trust India Alliance Affordable Approaches to Cancer

Investigating therapeutic application of PARP inhibitor as chemo-radiosensitser in cervical cancer and its effect on renal protection. NJ Curtin (PI) Academy of Medical Sciences £99,000 (2019-2021)

Increasing the therapeutic application of PARP inhibitors in ovarian cancer by inhibiting DNA repair. NJ Curtin (PI), R O’Donnell, Y Drew, A Mukhopadhyay. JGWP £49,950 (2017-2018)

Systems Medicine of Metabolic Signalling Networks: A New Concept for Breast Cancer Stratification. (K. Thedieck Co-ordinator, Groningen, Netherlands) Horizon 2020 £258,700

Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities. D Tweddle and NJ Curtin co-applicants Little Princess Trust £100,000 (01/09/2017-31/08/2020)

NEOCATS – Northern nEoadjuvant Ovarian CAncer Translational Study. Y Drew, R O’Donnell and NJ Curtin 缅北禁地 Healthcare Charity £289,163 01/03/2018-29/02/2020

Investigating BRCAness in epithelial ovarian cancer (EOC) in India to develop stratified surgical and chemotherapy options. NJ Curtin (UK PI) A Mukhopadhyay (India PI) DST-UKIERI (British Council) £78,470 April 2017-March 2021

Understanding synthetic lethality of ATR inhibitors with DDR dysregulation common in ovarian cancer. NJ Curtin (PI) Y Drew, F Zenke (Merck) £141,636 MRC Industrial CASE 1/10/2016- 25/12/2020

Funding (Previous)

Grant income for previous 10 years as PI £1,981,200 from Industry, £587,500 from Cancer Charities and £68,000 from Research Councils. Co. I. £10 million from Charities and £211,000 from Industry

Patents

1.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., and Golding, B. T.  Benzamide Analogues ADPRT (PARP) Inhibitors. Patent Application Number PCT/GB95/00513 (1995)

2.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Benzimidazole PARP Inhibitors.Patent Application Number PCT/GB96/01832.

3.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T.  Prodrugs of PARP Inhibitors.Patent Application Number PCT/GB97/02701.5

4.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Pyrimidopyrimidine Compounds.  Patent Application Number PCT/GB97/06618.7.

5.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T., Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Purine CDK Inhibitors. Patent Application Number PCT/GB97/14603.9

6.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Pyrimidine CDK Inhibitors. Patent Application Number PCT/GB98/06739.0

7.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Dipyridamole analogues. Patent Application Number PCT/GB98/00966

8.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. Golding, B. T., Hardcastle I, Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Anilinopurine CDK Inhibitors. Patent Application Number PCT/GB01/01686.4

9.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. DNA-PK inhibitors – 1 Patent Application Number PCT/GB01/19865.4 GB/14.08.01/GBA0119865.4

10.   Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. DNA-PK inhibitors-2. Patent Application Number PCT/GB01/19863.9

11.   Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. DNA-PK inhibitors-3. Patent Application Number 04014411.4

12.   Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. Thiopyran-4-ones as DNA-PK inhibitors. Patent Application Number PCT/GB2002/003740

13.   Helleday T and Curtin NJ. Therapeutic Compounds (PARP inhibitors in homologous repair/BRCA defective cancer) Patent Application Number PCT/GB2004/003183. Publication number WO 2005/012305 A2 Divisional application 16th April 2004 GB 0408524.7

14.   缅北禁地 Inventors. Calvert AH, Curtin NJ, Jones C, Newell DR, Plummer ER and Thomas HR.  Therapeutic Combinations Comprising PARP inhibitor US application No. 60/612,458 Filed 22nd September 2004 WO/2006/033006) THERAPEUTIC COMBINATIONS COMPRISING POLY(ADP-RIBOSE) POLYMERASES INHIBITOR

15.   Falcon S, Reaper P, Pollard J, Curtin NJ, Middleton FK and Chen T. Method for measuring ATR inhibition mediated increases in DNA damage. US patent application#14/045,373

 

Industrial Relevance

Much of my work has been in collaboration with Pharmaceutical companies and has been financially supported by: Agouron Pharmaceuticals, Astra Zeneca, BioMarin, BiPar Sciences, Clovis, Cyclacell, Eli Lilley, KuDOS, Merck, Pfizer, and Vertex Pharmaceuticals. I consult for: Abbot, BioMarin, Eisai, Tesaro

Teaching

Undergraduate Teaching

Personal Tutor

Supervisor of final year projects and Erasmus Students

Lecture on PED306

 

Postgraduate Teaching

MSc Oncology and Palliative Care Module leader: Pharmacology of Anticancer Drugs 

MRes Project supervisor 

Publications
  • Southgate HED, Chen L, Tweddle DA, Curtin NJ. . Cancers 2020, 12(5), 1095.
  • Bradbury A, O'Donnell R, Drew Y, Curtin NJ, Sharma Saha S. . Cancers 2020, 12(7), 1939.
  • Smith HL, Southgate H, Tweddle DA, Curtin NJ. . Expert Reviews in Molecular Medicine 2020, 22, e2.
  • Smith H, Prendergast L, Curtin NJ. . Cancers 2020, 12(4), 878.
  • Curtin NJ, Szabo C. . Nature Reviews Drug Discovery 2020, 19(10), 711-736.
  • Curtin N, Banyai K, Thaventhiran J, Le Quesne J, Helyes Z, Bai P. . British Journal of Pharmacology 2020, 177(16), 3635-3645.
  • Bradbury A, Hall S, Curtin N, Drew Y. . Pharmacology and Therapeutics 2020, 207, 107450.
  • Southgate HED, Chen L, Curtin NJ, Tweddle DA. . Frontiers in Oncology 2020, 10, 371.
  • Curtin NJ. . Cancers 2020, 12(3), 564.
  • Mukhopadhyay A, Drew Y, Matheson E, Salehan M, Gentles L, Pachter JA, Curtin NJ. . Biochemical Pharmacology 2019, 167, 125-132.
  • Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL. . Cancers 2019, 11(3), 354.
  • Unterlass JE, Curtin NJ. . Expert Reviews in Molecular Medicine 2019, 21, e4.
  • Curtin NJ, Drew Y, Sharma-Saha S. . Nature Reviews Clinical Oncology 2019, 16, 725–726.
  • Franklin M, Gentles L, Matheson E, Bown N, Cross P, Ralte A, Gilkes-Immeson C, Bradbury A, Zanjirband M, Lunec J, Drew Y, O'Donnell R, Curtin NJ. . Cancer Medicine 2018, 7(9), 4744-4754.
  • Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. . Blood Advances 2018, 2(10), 1157-1169.
  • Berger NA, Besson VC, Boulares AH, Burkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Hasko G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sumegi B, Swanson RA, Szabo C. . British Journal of Pharmacology 2018, 175(2), 192-222.
  • Middleton FK, Pollard JR, Curtin NJ. . Cancers 2018, 10(8), 275.
  • Unterlass JE, Baslé A, Blackburn TJ, Tucker J, Turlais F, Cano C, Noble MME, Curtin NJ. . Oncotarget 2018, 9, 13139-13153.
  • Tomassini S, Gentles L, Kirk C, Cross P, Thomas H, Wedge S, Curtin NJ, O'Donnell RL. . In: BASO - The Association for Cancer Surgery Annual Scientific Conference and the NCRI Cancer Conference. 2017, Liverpool: Elsevier.
  • Zanjirband M, Curtin N, Edmondson RJ, Lunec J. . Oncotarget 2017, 8(41), 69779-69796.
  • McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ. . Clinical Cancer Research 2017, 23(8), 2050-2060.
  • Patterson MJ, Drew Y, Curtin NJ. . In: Cancer Therapeutic Targets. New York: Springer, 2017, pp.913-934.
  • Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ. . NMR in Biomedicine 2017, 30(9), e3736.
  • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. . Cancer Discovery 2017, 7(6), 620-629.
  • Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N. . Oncotarget 2017, 8(69), 113418-113430.
  • Canan S, Maegley K, Curtin NJ. . In: Methods in Molecular Biology. New York: Humana Press Inc, 2017, pp.271-297.
  • Unterlass JE, Wood RJ, Basle A, Tucker J, Cano C, Noble MM, Curtin NJ. . Oncotarget 2017, 8(61), 104478-104491.
  • Abdulrahman GO, Curtin NJ. . In: Samuel Chackalamannil, David Rotella and Simon Ward, ed. Comprehensive Medicinal Chemistry III. Elsevier Inc, 2017, pp.104-133.
  • Rundle S, Bradbury A, Drew Y, Curtin NJ. . Cancers 2017, 9(5), 41.
  • Shall S, Gaymes T, Farzaneh F, Curtin NJ, Mufti GJ. . In: Methods in Molecular Biology. New York: Humana Press Inc, 2017, pp.343-370.
  • O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, Curtin NJ. . International Journal of Gynecological Cancer 2016, 26(6), 1004-1011.
  • Alsubhi N, Middleton F, Abdel-Fatah TMA, Stephens P, Doherty R, Arora A, Moseley PM, Chan SYT, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S. . Molecular Oncology 2016, 10(2), 213-223.
  • Dent BM, Ogle LF, O'Donnell RL, Hayes N, Mallick U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FEB, Jamieson D. . International Journal of Cancer 2016, 138(1), 206-216.
  • Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NC, Jamieson D, Reeves HL. . Journal of Hepatology 2016, 65(2), 305-313.
  • Kotsopoulos IC, Begbie JA, Mukhopadhyay A, Lunec J, Curtin NJ, Kucukmetin A. . In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
  • Abdulrahman GO, Davison E, Matheson E, Drew Y, Curtin N, Mukhopadhyay A. . In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
  • Massey AJ, Stephens P, Rawlinson R, McGurk L, Plummer R, Curtin NJ. . Molecular Oncology 2016, 10(1), 101-112.
  • Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. . British Journal of Cancer 2016, 114(7), 723-730.
  • Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ. . International Journal of Gynecological Cancer 2016, 26(4), 763-769.
  • Matheson E, Salehan M, Mukhopadhyay A, Curtin NJ, Drew Y. . In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
  • Dearman C, Sharma RA, Curtin NJ. . In: PARP Inhibitors for Cancer Therapy. Cham: Humana Press Inc, 2015, pp.553-579.
  • Esfandiari A, Curtin NJ, Lunec J. . In: AACR 106th Annual Meeting 2015. 2015, Philadelphia, Pennsylvania: American Association for Cancer Research.
  • Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FEB, Allan JM, Pollard JR, Curtin NJ. . Oncotarget 2015, 6(32), 32396-32409.
  • McCormick A, Donoghue P, Dixon M, O'Donnell R, Kaufmann A, Curtin N, Edmondson R. . In: Blair Bell Research Society. 2015, Wiley-Blackwell Publishing Ltd.
  • Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR, Curtin NJ. . Molecular Oncology 2015, 9(2), 463-472.
  • Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL. . Clinical Cancer Research 2015, 21(4), 925-933.
  • Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NYR, Curtin NJ, Elmquist WF, Sarkaria JN. . Molecular Cancer Therapeutics 2015, 14(12), 2735-2743.
  • Vormoor B, Schlosser Y, Blair H, Wilkinson S, Newell DR, Curtin N. . In: 47th Congress of the International Society of Paediatric Oncology (SIOP). 2015, Cape Town, South Africa: Wiley-Blackwell.
  • O'Donnell RL, Kaufman A, Woodhous L, McCormick A, Curtin NJ, Edmondson R. . In: Annual Meeting of the Blair Bell Research Society. 2015, Royal College of Obstetricians and Gynaecologists, London: Wiley-Blackwell.
  • Wang DD, Li CZ, Sun W, Zhang SZ, Shalinsky DR, Kern KA, Curtin NJ, Sam WJ, Kirkpatrick TR, Plummer R. . Clinical Pharmacology in Drug Development 2015, 4(2), 89-98.
  • Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patternson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. . Oncotarget 2015, 6(41), 43978-43991.
  • McCormick A, Nakjang S, Donoghue P, Curtin N, Edmondson R. . In: 19th International Meeting of the European Society of Gynecological Oncology (ESGO 2015). 2015, Nice, France: Lippincott Williams & Wilkins.
  • Unterlass JE, Aljufri N, Bex S, Cano C, Noble MEM, Curtin NJ. . In: AACR 106th Annual Meeting 2015. 2015, Philadelphia, PA, USA: American Association for Cancer Research.
  • Abdel-Fatah TMA, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S. . Molecular Oncology 2015, 9(3), 569-585.
  • McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. . PLoS One 2015, 10(2).
  • Patterson MJ, Sutton RJ, Forrest I, Sharrock R, Lane M, Kaufmann A, O'Donnell R, Edmondson R, Wilson BT, Curtin N. . British Journal of Cancer 2014, 111(1), 94-100.
  • Ogle L, Jamieson D, O'Donnell R, Dent B, Boddy A, Curtin N, Plummer R, Reeves H, Clinical and Translational Group. . In: The International Liver Congress 2014: 49th Annual Meeting of the European Association for the Study of the Liver. 2014, London: Elsevier BV.
  • Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. . Breast Cancer Research and Treatment 2014, 143(1), 47-55.
  • Veuger S, Curtin NJ. . In: Cancer Drug Design and Discovery. London: Academic Press, 2014, pp.193-237.
  • Curtin N. . Biochemical Society Transactions 2014, 42(1), 82-88.
  • Curtin NJ. . Cell Cycle 2014, 13(20), 3161-3162.
  • Vormoor B, Curtin NJ. . Current Opinion in Oncology 2014, 26(4), 428-433.
  • Znojek P, Willmore E, Curtin NJ. . British Journal of Cancer 2014, 111(7), 1319-1326.
  • O'Donnell RL, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufmann A, Soohoo S, Elattar A, Curtin NJ, Edmondson RJ. . PLoS ONE 2014, 9(3), e90604.
  • Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. . British Journal of Cancer 2014, 110, 1977-1984.
  • Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GCM, Thommes P, Ting A, Griffin RJ. . Journal of Medicinal Chemistry 2013, 56(16), 6386-6401.
  • Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H. . Cancer Chemotherapy and Pharmacology 2013, 71(5), 1191-1199.
  • Middleton FK, Curtin NJ. . In: Advances in DNA Repair in Cancer Therapy. New York: Springer, 2013, pp.211-228.
  • Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJR, Cox A, Curtin NJ, Dekker LV, Silva ID, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans DG, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JMW, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin LA, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JPB, O'Connor R, Palmieri C, Pharoah PDP, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt ANJ, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM. . Breast Cancer Research 2013, 15(5), 1-37.
  • Curtin NJ. . British Journal of Pharmacology 2013, 169(8), 1745-1765.
  • Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S, Mufti GJ. . Haematologica 2013, 98(9), 1397-1406.
  • McCormick A, Dixon M, ODonnell R, Curtin NJ, Edmondson RJ. Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib. In: CLINICAL CANCER RESEARCH. 2013, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH.
  • Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NMB, Lau A, Newell DR, Curtin NJ. . Molecular Cancer Therapeutics 2013, 12(6), 959-967.
  • Curtin NJ, Szabo C. . Molecular Aspects of Medicine 2013, 34(6), 1217-1256.
  • Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson C, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear KA, Slade A, Thommes P, Martin NMB, Newell DR, Smith GCM, Curtin NJ. . Molecular Cancer Therapeutics 2012, 11(8), 1789-1798.
  • Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ. . Cancer Research 2012, 72(22), 5675-5682.
  • Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. . Cancer Treatment Reviews 2012, 38(2), 89-100.
  • Curtin NJ. . Nature Reviews Cancer 2012, 12(12), 801-817.
  • Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. . Cancer Chemotherapy and Pharmacology 2012, 69(1), 155-164.
  • Curtin NJ. . Drug Discovery Today: Disease Models 2012, 9(2), e51-e58.
  • Chen T, Stephens PA, Middleton FK, Curtin NJ. . Drug Discovery Today 2012, 17(5-6), 194-202.
  • Shall S, Gaymes T, Farzaneh F, Curtin N, Mufti GJ. . In: Tulin, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2012, pp.239-66.
  • Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. . Breast 2012, 21(1), 20-26.
  • Spagnolo L, Barbeau J, Curtin NJ, Morris EP, Pearl LH. . Nucleic Acids Research 2012, 40(9), 4168-4177.
  • Johnson N, Li YC, Walton ZE, Cheng KA, Li DA, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. . Nature Medicine 2011, 17(7), 875-882.
  • Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. . British Journal of Cancer 2011, 105(3), 372-381.
  • Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. . Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
  • Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY 2011, 118(4), 429-432.
  • Mukhopadhyay A, Curtin NJ, Plummer ER, Edmondson RJ. . BJOG 2011, 118(4), 429-432.
  • Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ. . Biochemical Journal 2011, 436(3), 671–679.
  • Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. . European Journal of Cancer 2011, 47(13), 2052-2059.
  • Canan S, Maegley K, Curtin N. . In: Virag, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2011, pp.463-89.
  • Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GCM, Leung HY, Curtin NJ, Robson CN. . PLoS One 2011, 6(5), e20311.
  • Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. . Molecular Cancer Therapeutics 2011, 10(12), 2320-2329.
  • Javle M, Curtin NJ. . Therapeutic Advances in Medical Oncology 2011, 3(6), 257-267.
  • Javle M, Curtin NJ. . British Journal of Cancer 2011, 105(8), 1114-1122.
  • Drew Y, Mulligan EA, Vong W, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. . Journal of the National Cancer Institute 2011, 103(4), 334-346.
  • Issaeva N, Thomas HD, Djurenovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T. . Cancer Research 2010, 70(15), 6268-6276.
  • Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. . British Journal of Cancer 2010, 103(10), 1588-1596.
  • Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ. . Clinical Cancer Research 2010, 16(8), 2344-2351.
  • Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ. . Journal of Medicinal Chemistry 2010, 53(24), 8498-8507.
  • Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ. . Cancer Chemotherapy and Pharmacology 2010, 66(4), 807-812.
  • Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, Curtin NJ. . British Journal of Cancer 2010, 102(2), 342-350.
  • Marchetti F, Cano C, Curtin NJ, Golding BT, Griffin RJ, Haggerty K, Newell DR, Parsons RJ, Payne SL, Wang LZ, Hardcastle IR. . Organic & Biomolecular Chemistry 2010, 8(10), 2397-2407.
  • Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN. . Molecular Cancer Therapeutics 2009, 8(2), 407-414.
  • Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. . Clinical Cancer Research 2009, 15(4), 1241-1249.
  • Mitchell J, Smith GCM, Curtin NJ. . International Journal of Radiation: Oncology - Biology - Physics 2009, 75(5), 1520-1527.
  • Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ. . British Journal of Cancer 2009, 101(2), 256-262.
  • Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ. . Molecular Cancer Therapeutics 2009, 8(7), 1828-1837.
  • Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ. . Clinical Cancer Research 2009, 15(19), 6106-6112.
  • Murr M, Cano C, Golding BT, Hardcastle IR, Hummersome M, Frigerio M, Curtin NJ, Menear K, Richardson C, Smith G, Griffin R. . Bioorganic and Medicinal Chemistry Letters 2008, 18(17), 4885-4890.
  • Plummer ER, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin NJ, Boddy AV, McHugh P, Newell DR, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert AH. . Clinical Cancer Research 2008, 14(23), 7917-7923.
  • Scrace SF, Kierstan P, Borgognoni J, Wang LZ, Denny S, Wayne J, Bentley C, Cansfield AD, Jackson PS, Lockie AM, Curtin NJ, Newell DR, Williamson DS, Moore JD. . Cell Cycle 2008, 7(24), 3898-3907.
  • Zaremba T, Curtin NJ. . Anti-Cancer Agents in Medicinal Chemistry 2007, 7(5), 515-523.
  • Thomas HD, Calabrese CR, Batey M, Canan S, Hostomsky Z, Kyle S, Maegley K, Newell DR, Skalitzky D, Wang L, Webber SE, Curtin NJ. . Molecular Cancer Therapeutics 2007, 6(3), 945-956.
  • Hollick J, Rigoreau L, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone M, Menear K, Martin N, Matthews I, Newell DR, Ord R, Richardson C, Smith G, Griffin RJ. . Journal of Medicinal Chemistry 2007, 50(8), 1958-1972.
  • Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR. . Organic and Biomolecular Chemistry 2007, 5(10), 1577-1585.
  • Rigas AC, Robson CN, Curtin NJ. . Oncogene 2007, 26(55), 7611-7619.
  • Curtin NJ. . Expert Opinion on Therapeutic Targets 2007, 11(6), 783-799.
  • Zhao Y, Thomas HD, Batey M, Cowell I, Richardson C, Griffin RJ, Calvert AH, Newell DR, Smith G, Curtin NJ. . Cancer Research 2006, 66(10), 5354-5362.
  • Griffin RJ, Henderson A, Curtin NJ, Echalier A, Endicott J, Hardcastle IR, Newell DR, Noble M, Wang L, Golding BT. . Journal of the American Chemical Society 2006, 128(18), 6012-6013.
  • Hardcastle I, Cockcroft X, Curtin NJ, El-Murr M, Leahy JJJ, Stockley M, Golding BT, Rigoreau L, Richardson C, Smith G, Griffin RJ. . Journal of Medicinal Chemistry 2005, 48(24), 7829-7846.
  • Fishel M, Newell D, Griffin R, Davison R, Wang L, Curtin NJ, Zuhowski E, Kasza K, Egorin M, Moschel R, Dolan M. . Journal of Pharmacology and Experimental Therapeutics 2005, 312(1), 206-213.
  • Hardcastle I, Ahmed S, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin R, Guyenne S, Hutton C, Källblad P, Kemp S, Kitching M, Newell D, Norbedo S, Northen J, Reid R, Saravanan K, Willems H, Lunec J. . Bioorganic and Medicinal Chemistry Letters 2005, 15(5), 1515-1520.
  • Curtin NJ. . Expert Reviews in Molecular Medicine 2005, 7(4), 1-20.
  • Curtin NJ. . Expert Reviews in Molecular Medicine 2005, 7(4), 1-20.
  • Pennati M, Campbell AJ, Curto M, Binda M, Cheng Y, Wang L, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IR, Henderson A, Zaffaroni N, Newell DR. . Molecular Cancer Therapeutics 2005, 4(9), 1328-1337.
  • Bryant H, Schultz N, Thomas HD, Parker K, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. . Nature 2005, 434(7035), 913-917.
  • Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ. . Clinical Cancer Research 2005, 11(9), 3402-3409.
  • Smith LM, Willmore E, Austin C, Curtin NJ. . Clinical Cancer Research 2005, 11(23), 8449-8457.
  • Calabrese C, Almassy R, Barton S, Batey M, Calvert AH, Canan-Koch S, Durkacz B, Hostomsky Z, Kumpf R, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford I, Skalitzky D, Thomas HD, Wang L, Webber S, William K, Curtin NJ. . Journal of the National Cancer Institute 2004, 96(1), 56-67.
  • Tikhe J, Webber S, Hostomsky Z, Maegley K, Ekkers A, Li J, Yu X, Almassy R, Kumpf R, Boritzki T, Zhang C, Calabrese C, Curtin NJ, Kyle S, Thomas HD, Wang L, Calvert AH, Golding B, Griffin RJ, Newell DR. . Journal of Medicinal Chemistry 2004, 47(22), 5467-5481.
  • Veuger SJ, Curtin NJ, Smith GCM, Durkacz BW. . Oncogene 2004, 23(44), 7322–7329.
  • Veuger SJ, Curtin NJ, Smith G, Durkacz BW. . Oncogene 2004, 23(44), 7322-7329.
  • Hickson, I., Zhao, Y., Richardson, C., Green, S., Martin, N., Orr, A., Reaper, P., Jackson, S., Curtin, N.J., Smith, G. . Cancer Research 2004, 64(24), 9152-9159.
  • Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury, P., Menyerol, J., Mesguiche, V., Newell, D.R., Noble, M., Pratt, D., Wang, L., Whitfield, H.J. . Journal of Medicinal Chemistry 2004, 47(15), 3710-3722.
  • Curtin NJ, Wang L, Yiakouvaki A, Kyle S, Arris C, Canan-Koch S, Webber S, Durkacz BW, Calvert AH, Hostomsky Z, Newell DR. . Clinical Cancer Research 2004, 10(3), 881-889.
  • White, A., Curtin, N.J., Eastman, B., Golding, B.T., Hostomsky, Z., Kyle,S., Li, J., Maegley, K., Skalitzky, D., Webber, S., Yu, X., Griffin, R.J. . Bioorganic and Medicinal Chemistry Letters 2004, 14(10), 2433-2437.
  • Curtin, N., Barlow, H., Bowman, K., Calvert, A. H., Davison, R., Golding, B., Huang, B., Loughlin, P., Newell, D., Smith, P., Griffin, R. . Journal of Medicinal Chemistry 2004, 47(20), 4905-4922.
  • Mesguiche, V, Parsons, R.J., Arris, C.E., Bentley, J., Boyle, F., Curtin, N.J., Davies, T.G., Endicott, J., Gibson, A., Golding, B., Griffin, R.J., Jewsbury, P., Johnson, L.N., Newell, D.R., Noble, M.E.M., Wang, L., Hardcastle, I.R. . Bioorganic and Medicinal Chemistry Letters 2003, 13(2), 217-222.
  • Calabrese C, Batey M, Thomas HD, Durkacz B, Wang L, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ. . Clinical Cancer Research 2003, 9(7), 2711-2718.
  • Veuger, S., Curtin, N.J., Richardson, C., Smith, G., Durkacz, B.W. . Cancer Research 2003, 63(18), 6008-6015.
  • Sayle, K., Bentley, J., Boyle, F., Calvert, A. H., Cheng, Y., Curtin, N. J., Endicott, J., Golding, B., Hardcastle, I., Jewsbury, P., Mesguiche, V., Newell, D. R., Noble, M., Parsons, R., Pratt, D., Wang, L., Griffin, R. J. . Bioorganic and Medicinal Chemistry Letters 2003, 13(18), 3079-3082.
  • Skalitzky, D., Marakovits, J., Maegley, K., Ekker, A., Yu, X., Hostomsky, Z., Webber, S., Eastman, B., Almassy, R., Li, J., Curtin, N. J., Newell, D. R., Calvert, A. H., Griffin, R. J., Golding, B. T. . Journal of Medicinal Chemistry 2003, 46(2), 210-213.
  • Northen J, Boyle F, Clegg W, Curtin NJ, Edwards A, Griffin R, Golding B. . Journal of the Chemical Society. Perkin Transactions 1 2002, 2(1), 108-115.
  • Monks, N., Blakey, D., East, S., Dowell, R., Calvete, J., Curtin, N.J., Arris, C.E., Newell, D.R. . European Journal of Cancer 2002, 38(11), 1543-1552.
  • Koch SSC, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li JK, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z. . Journal of Medicinal Chemistry 2002, 45(23), 4961-4974.
  • Gibson A, Arris CE, Bentley J, Boyle F, Curtin NJ, Davies T, Endicott J, Golding BT, Grant S, Griffin R, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J., Whitfield, H.J. . Journal of Medicinal Chemistry 2002, 45(16), 3381-3393.
  • Davies T, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott J, Gibson A, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J.A., Wang, L., Whitfield, H.J. . Nature Structural Biology 2002, 9(10), 745-749.
  • Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. . Clinical Cancer Research 2001, 7(7), 2114-2123.
  • Bowman, K. J., Newell, D. R., Calvert, A. H., Curtin, N. J. . British Journal of Cancer 2001, 84(1), 106-112.
  • Marshman, E., Taylor, G., Thomas, H., Newell, D.R., Curtin, N.J. . Biochemical Pharmacology 2001, 61(4), 477-484.
  • Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ. . Clinical Cancer Research 2001, 7(7), 2105-2113.
  • Monks, N., Blakey,D., Curtin, N.J., East, S., Heuze, A., Newell, D.R. . British Journal of Cancer 2001, 85(5), 764-771.
  • Curtin, N.J., Hughes, A.N. . Lancet Oncology 2001, 2(5), 298-306.
  • Lu, X., Errington, J., Chen, V., Curtin, N. J., Boddy, A. V., Newell, D. R. . Clinical Cancer Research 2000, 6(1), 271-277.
  • Monks, N., Calvete, J., Curtin, N.J., Blakey, D., East, S., Newell, D.R. . British Journal of Cancer 2000, 83(2), 267-269.
  • Smith, P., Marshman, E., Newell, D.R., Curtin, N.J. . British Journal of Cancer 2000, 82(4), 924-930.
  • Arris, C. E., Boyle, F., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Grant, S., Griffin, R. J., Jewsbury, P., Johnson, L., Lawrie, A., Newell, D. R., Noble, M., Sausville, E., Schultz, R., Yu, W. . Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
  • Delaney, C.A., Wang, L., Kyle, S., White, A.W., Calvert, A.H., Curtin, N.J., Durkacz, B.W., Hostomsky, Z, Newell, D.R. . Clinical Cancer Research 2000, 6(7), 2860-2867.
  • Griffin, R. J., Arris, C. E., Bleasdale, C. , Boyle, F., Calvert, A. H., Curtin, N. J., Dalby, C., Kanugula, S., Lembicz, N., Newell, D. R., Pegg, A., Golding, B. T. . Journal of Medicinal Chemistry 2000, 43(22), 4071-4083.
  • White, A.W., Almassy, R., Calvert, A.H., Curtin, N.J., Griffin, R.J., Hostomsky, Z., Maegley, K., Newell, D.R., Srinivasan, S, Golding, B.T. . Journal of Medicinal Chemistry 2000, 43(22), 4084-4097.
  • Barlow, H. C., Bowman, K. J., Curtin, N. J., Calvert, A. H., Golding, B. T., Huang, B., Loughlin, P. J., Newell, D. R., Smith, P. G., Griffin, R. J. . Bioorganic and Medicinal Chemistry Letters 2000, 10(6), 585-589.
  • Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN, Noble MEM, Newell DR. . Clinical Cancer Research 2000, 6, 328.
  • Curtin, N.J., Turner, D.P. . European Journal of Cancer 1999, 35(6), 1020-1026.
  • Curtin, N.J., Bowman, K., Turner, R., Huang, B., Loughlin, P., Calvert, A.H., Golding, B.T., Griffin, R.J., Newell, D.R. . British Journal of Cancer 1999, 80(11), 1738-1746.
  • Smith, P.G., Marshman, E., Calvert, A., Newell, D.R., Curtin, N.J. . Seminars in Oncology 1999, 26(2), 63-67.
  • Marshman, E., Newell, D.R., Calvert, A.H., Dickinson, A., Patel, H., Campbell, F., Curtin, N.J. . Clinical Cancer Research 1998, 4(11), 2895-2902.
  • Bowman, J., White, A.W., Golding, B.T., Griffin, R.J., Curtin, N.J. . British Journal of Cancer 1998, 78(10), 1269-1277.
  • Griffin, R. J., Srinivasan, S., Bowman, K., Calvert, A. H., Curtin, N. J., Newell, D. R., Pemberton, L. C., Golding, B. T. . Journal of Medicinal Chemistry 1998, 41(26), 5247-5256.
  • Turner, R., Aherne, G., Curtin, N.J. . British Journal of Cancer 1997, 76(10), 1300-1307.
  • Turner, R., Curtin, N.J. . British Journal of Cancer 1996, 73(7), 856-860.
  • Griffin, R.J., Srinivasan, S., White, A.W., Bowman, K., Calvert, A.H., Curtin, N.J., Newell, D.R., Golding, B.T. . Pharmaceutical Sciences 1996, 2(1), 43-47.
  • Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. . Biochimie 1995, 77(6), 408-422.
  • Arris, C. E., Bleasdale, C., Calvert, A. H., Curtin, N. J., Dalby, C., Golding, B. T., Griffin, R. J., Lunn, J. M., Major, G. N., Newell, D. R. . Anti-Cancer Drug Design 1994, 9(5), 401-408.
  • Curtin, N. J., Harris, A. L., Aherne, G. W. . Cancer Research 1991, 51(9), 2346-2352.
  • Curtin NJ, Newell DR, Harris AL. . Biochemical Pharmacology 1989, 38(19), 3281-8.
  • Piall, E. M., Curtin, N. J., Aherne, G. W., Harris, A. L., Marks, V. . Analytical Biochemistry 1989, 177(2), 347-352.
  • Curtin NJ, Harris AL. . Biochemical Pharmacology 1988, 37(11), 2113-20.
  • Bassendine MF, Curtin NJ, Loose H, Harris AL, James OF. . Journal of Hepatology 1987, 4(3), 349-56.
  • Curtin NJ, Harris AL, James OFW, Bassendine MF. . British Journal of Cancer 1986, 53(3), 361-368.
  • Curtin NJ, Snell K. . British Journal of Cancer 1983, 48(4), 495-505.
  • Margison GP, Curtin NJ, Snell K, Craig AW. . British Journal of Cancer 1979, 40(5), 809-813.